A new cheaper version of antiviral remdesivir has been launched locally by a Indian licensee, while Chinese vaccine developers push forward with broader trials of their candidates.
Zydus Cadila has launched the most economical brand of remdesivir, licensed from Gilead Sciences, Inc., in India. Priced at INR2,800 ($37) per 100mg injection, Remdac is nearly 50% cheaper than the highest-cost Indian brand of the drug.
In June 2020, Zydus entered into a non-exclusive agreement with Gilead to manufacture and sell remdesivir, which has emergency use authorization from the U.S. Food and Drug Administration (FDA)
Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.
A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.
Pfizer’s and Moderna’s quarterly pandemic-related product sales could not mask other weaknesses while GSK’s quarter was marred by unimpressive non-pandemic vaccines sales.
Japanese distributor Meiji Seika Pharma is considering possible legal action against what it views as online slander around COVID-19 vaccine Kostaive, which received its global-first approval in Japan last year and has now been launched for regular vaccination in the country.
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.
Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.
Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.
